

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently Amended)** A membrane translocation peptide carrier moiety consisting of

(a) RRMKWKK (SEQ ID NO: 2);

1 7

(b) SEQ ID No 2, wherein one to three amino acid residues are replaced by a naturally or non-naturally occurring amino acid residue;

(c) SEQ ID No 2, wherein the order of two or more amino acid residues is reversed;

(d) SEQ ID No 2, wherein both (b) and (c) are present together;

(e) SEQ ID No 2, wherein one or more amino acid residues are in peptoid form;

(f) SEQ ID No 2, wherein the (N-C-C) backbone of one or more amino acid residues of the peptide carrier moiety has been modified; or

(g) SEQ ID NO:2, having any of (b)-(f) in combination.

Claims 2-48 **(Canceled)**

49. **(Currently Amended)** A carrier moiety according to claims 1, 77, 79 or 81, wherein one to three amino acid residues are replaced by homologous replacement.

50. **(Canceled)**

51. **(Currently Amended)** A carrier moiety according to claims 1, 77, 79

or 81, wherein one to three amino acid residues are replaced by non-homologous replacement.

52. **(Canceled)**

53. **(Previously Presented)** A carrier moiety according to claim 51, wherein the replacement amino acid is a non-natural amino acid selected from the group consisting of: alpha* and alpha-disubstituted* amino acids, N-alkyl amino acids*, lactic acid*, halide derivatives of natural amino acids, L-allyl-glycine*, β -alanine*, L- α -amino butyric acid*, L- γ -amino butyric acid*, L- α -amino isobutyric acid*, L- ϵ -amino caproic acid[#], 7-amino heptanoic acid*, L-methionine sulfone^{##}, L-norleucine*, L-norvaline*, p-nitro-L-phenylalanine*, L-hydroxyproline[#], L-thiopropine*, and methyl derivatives of phenylalanine (Phe), L-Phe (4-amino)[#], L-Tyr (methyl)*, L-Phe (4-isopropyl)*, L-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid)*, L-diaminopropionic acid [#] and L-Phe (4-benzyl)*, wherein the notation * indicates that the derivative is hydrophobic.

54. **(Currently Amended)** A carrier moiety according to claims 1, 78, 79 or 81, wherein the order of the second and third amino acids from the C-terminal end of the peptide is reversed.

Claims 55-58 **(Canceled)**

59. **(Currently Amended)** A carrier moiety according to claim 1 or 81, wherein one or more amino acid[[s]] residues are in peptoid form.

60. **(Currently Amended)** A carrier moiety according to claims 1, 77, 79 or 81, wherein one to three amino acid residues at any of positions 1, 2, 3, 5, 6 or 7 of said formula (SEQ ID No. 2) are replaced by a naturally or non-naturally occurring amino acid.

61. **(Currently Amended)** A carrier moiety according to claims 1, 78, 79

or 81, wherein the order of two amino acid residues at any of positions 2 and 3, 3 and 4, 4 and 5, or 5 and 6 of said formula (SEQ ID No. 2) are reversed.

62. **(Currently Amended)** A carrier moiety according to claim[[s]] 60, wherein the amino acid residue at position 3 or 7 of said formula (SEQ ID No. 2) is replaced.

63. **(Previously Presented)** A carrier moiety according to claim 60, wherein the amino acid residue at position 3 of said formula (SEQ ID No. 2) is replaced.

64. **(Previously Presented)** A carrier moiety according to claim 61, wherein the order of the amino acid residue at position 3 of said formula (SEQ ID No. 2) is reversed with the amino acid at position 2.

65. **(Previously Presented)** A carrier moiety according to claim 61, wherein the order of the amino acid residue at position 3 of said formula (SEQ ID No. 2) is reversed with the amino acid at position 4.

66. **(Currently Amended)** A carrier moiety according to claim[[s]] 49 wherein homologous replacement occurs at any of positions 1 and 2 of said formula (SEQ ID No. 2).

67. **(Currently Amended)** A carrier moiety according to claim[[s]] 51 [[or 53]], wherein non-homologous replacement occurs at any of positions 3, 4, 5 and 6 of said formula (SEQ ID No. 2).

68. **(Currently Amended)** A carrier moiety according to claims 1, 77, 79 or 81~~claims 1, 49 or 51~~, wherein two amino acid residues of said formula (SEQ ID No. 2) are replaced by homologous or non-homologous replacement.

69. **(Previously Presented)** A carrier moiety according to claim 68,

wherein amino acid residues at positions 2 and 3 of said formula (SEQ ID No. 2) are replaced.

70. **(Previously Presented)** A carrier moiety according to claim 68, wherein amino acid residues at positions 4 and 5 of said formula (SEQ ID No. 2) are replaced.

71. **(Currently Amended)** A carrier moiety according to claim 68, wherein amino acid residues at positions 5 and 6 of said formula (SEQ ID No. 2) are replaced.

72. **(Previously Presented)** A carrier moiety according to claim 53, wherein the halide derivative is selected from the group consisting of trifluorotyrosine*, p-Cl-phenylalanine*, p-Br-phenylalanine*, and p-I-phenylalanine*.

73. **(Previously Presented)** A carrier moiety according to claim 53, wherein the methyl derivative of phenylalanine (Phe) is selected from the group consisting of 4-methyl-Phe*, and pentamethyl-Phe*.

74. **(Currently Amended)** A carrier moiety ~~[[of]]~~according to claims 1, 76, 77, 78, 79, 80 or 81, wherein the free carboxyl group of the carboxy terminal amino acid residue is in the form -C(O)-NRR', wherein R and R' are each independently selected from the group consisting of: hydrogen, C1-6 alkyl, C1-6 alkylene or C1-6 alkynyl, aryl, each optionally substituted with a heteroatom.

75. **(Currently Amended)** A carrier moiety according to claim 74, wherein the free carboxyl group of the carboxy terminal amino acid residue is a carboxamide group.

76. **(New)** The membrane translocation peptide carrier moiety according to claim 1 consisting of RRMKWKK (SEQ ID NO: 2).

77. (New) The membrane translocation peptide carrier moiety according to claim 1, wherein one to three amino acid residues are replaced by a naturally or non-naturally occurring amino acid residue.

78. (New) The membrane translocation peptide carrier moiety according to claim 1, wherein the order of two or more amino acid residues is reversed.

79. (New) The membrane translocation peptide carrier moiety according to claim 1, wherein one to three amino acid residues are replaced by a naturally or non-naturally occurring amino acid residue and wherein the order of two or more amino acid residues is reversed.

80. (New) The membrane translocation peptide carrier moiety according to claim 1, wherein the (N-C-C) backbone of one or more amino acid residues of the peptide carrier moiety has been modified.

81. (New) The membrane translocation peptide carrier moiety according to claim 1, having at least two of the following in combination:

(a) SEQ ID No 2, wherein one to three amino acid residues are replaced by a naturally or non-naturally occurring amino acid residue;

(b) SEQ ID No 2, wherein the order of two or more amino acid residues is reversed;

(c) SEQ ID No 2, wherein both (b) and (c) are present together;

(d) SEQ ID No 2, wherein one or more amino acid residues are in peptoid form; or

(e) SEQ ID No 2, wherein the (N-C-C) backbone of one or more amino acid residues of the peptide carrier moiety has been modified.